UA42669A - Антагоністи ангіотензину ii, спосіб їх отримання (варіанти), проміжна сполука (варіанти), спосіб їх отримання та фармацевтична композиція - Google Patents
Антагоністи ангіотензину ii, спосіб їх отримання (варіанти), проміжна сполука (варіанти), спосіб їх отримання та фармацевтична композиціяInfo
- Publication number
- UA42669A UA42669A UA5010343A UA5010343A UA42669A UA 42669 A UA42669 A UA 42669A UA 5010343 A UA5010343 A UA 5010343A UA 5010343 A UA5010343 A UA 5010343A UA 42669 A UA42669 A UA 42669A
- Authority
- UA
- Ukraine
- Prior art keywords
- phenyl
- group
- hydrogen
- atom
- cyano
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 title 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 C1-C4alkoxycarbonyl Chemical group 0.000 abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Insulating Materials (AREA)
- Paints Or Removers (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9003563A FR2659967B1 (fr) | 1990-03-20 | 1990-03-20 | Derives d'imidazolinone n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
| FR9010144A FR2665702B1 (fr) | 1990-08-08 | 1990-08-08 | Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
| PCT/FR1991/000224 WO1991014679A1 (fr) | 1990-03-20 | 1991-03-20 | Derives heterocycliques n-substitues, leur preparation, les compostions pharmaceutiques en contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA42669A true UA42669A (uk) | 2001-11-15 |
Family
ID=26227935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA5010343A UA42669A (uk) | 1990-03-20 | 1991-03-20 | Антагоністи ангіотензину ii, спосіб їх отримання (варіанти), проміжна сполука (варіанти), спосіб їх отримання та фармацевтична композиція |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0454511B1 (en:Method) |
| JP (2) | JP2868313B2 (en:Method) |
| KR (1) | KR0175310B1 (en:Method) |
| AT (1) | ATE167475T1 (en:Method) |
| AU (1) | AU641005B2 (en:Method) |
| CA (1) | CA2057913C (en:Method) |
| CZ (2) | CZ287064B6 (en:Method) |
| DE (2) | DE69129606T2 (en:Method) |
| DK (1) | DK0454511T3 (en:Method) |
| ES (1) | ES2119764T3 (en:Method) |
| FI (1) | FI103407B (en:Method) |
| HU (3) | HUT67648A (en:Method) |
| IE (1) | IE910913A1 (en:Method) |
| IL (3) | IL110820A (en:Method) |
| LU (2) | LU90279I2 (en:Method) |
| LV (1) | LV10439B (en:Method) |
| MX (1) | MX9203586A (en:Method) |
| MY (1) | MY115638A (en:Method) |
| NL (2) | NL980039I2 (en:Method) |
| NO (3) | NO301977B1 (en:Method) |
| NZ (1) | NZ237476A (en:Method) |
| PL (3) | PL166581B1 (en:Method) |
| PT (1) | PT97078B (en:Method) |
| RU (1) | RU2099331C1 (en:Method) |
| SG (1) | SG49053A1 (en:Method) |
| SK (2) | SK283197B6 (en:Method) |
| TW (1) | TW201738B (en:Method) |
| UA (1) | UA42669A (en:Method) |
| WO (1) | WO1991014679A1 (en:Method) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2084801T3 (es) * | 1990-02-19 | 1996-05-16 | Ciba Geigy Ag | Acil compuestos. |
| CA2053148A1 (en) * | 1990-10-16 | 1992-04-17 | Karnail Atwal | Dihydropyrimidine derivatives |
| KR100222252B1 (ko) * | 1990-12-14 | 1999-10-01 | 스튜어트 알. 수터 | 안지오텐신 ii 수용체 차단 조성물 |
| FR2673427B1 (fr) * | 1991-03-01 | 1993-06-18 | Sanofi Elf | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
| AU1625192A (en) * | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
| IL102183A (en) * | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
| AU2496492A (en) * | 1991-08-19 | 1993-03-16 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazolinone derivatives |
| WO1993004046A1 (en) * | 1991-08-19 | 1993-03-04 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazolinone derivatives |
| US5182288A (en) * | 1991-11-13 | 1993-01-26 | Ortho Pharmaceutical Corporation | Substituted n-biphenylyl lactams |
| FR2685328B1 (fr) * | 1991-12-20 | 1995-12-01 | Rhone Poulenc Agrochimie | Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides. |
| IL104755A0 (en) * | 1992-02-17 | 1993-06-10 | Ciba Geigy Ag | Treatment of glaucoma |
| US5326776A (en) * | 1992-03-02 | 1994-07-05 | Abbott Laboratories | Angiotensin II receptor antagonists |
| FR2688781B1 (fr) * | 1992-03-23 | 1994-07-01 | Sanofi Elf | Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
| FR2689887B1 (fr) * | 1992-04-13 | 1995-06-23 | Sanofi Elf | Procede de preparation d'un derive de biphenyle. |
| EP0577025A3 (de) * | 1992-07-01 | 1998-02-04 | Hoechst Aktiengesellschaft | Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen |
| GB9218449D0 (en) | 1992-08-29 | 1992-10-14 | Boots Co Plc | Therapeutic agents |
| ATE204276T1 (de) * | 1992-12-22 | 2001-09-15 | Takeda Chemical Industries Ltd | Heterocyclische verbindungen mit angiotensin-ii- antagonistischer wirkung und ihre anwendung |
| FR2711367B1 (fr) * | 1993-10-19 | 1995-12-01 | Roussel Uclaf | Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus. |
| US5338740A (en) * | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| US5411641A (en) * | 1993-11-22 | 1995-05-02 | E. I. Du Pont De Nemours And Company | Electrochemical conversion of anhydrous hydrogen halide to halogen gas using a cation-transporting membrane |
| FR2725987B1 (fr) * | 1994-10-19 | 1997-01-10 | Sanofi Sa | Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive |
| SE9501881D0 (sv) * | 1995-05-19 | 1995-05-19 | Astra Ab | New pharmacological use of AII-receptor antagonists |
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| JPH11513395A (ja) * | 1995-10-06 | 1999-11-16 | ノバルティス・アクチエンゲゼルシャフト | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト |
| CA2196263C (en) * | 1996-02-09 | 2004-10-26 | Barry Jackson | Process for the preparation of 4-oxoimidazolinium salts |
| DK0883401T3 (da) | 1996-02-29 | 2003-05-05 | Novartis Ag | AT1-receptorantagonist til stimulering af apoptose |
| NZ331143A (en) * | 1996-03-14 | 2001-06-29 | Warner Lambert Co | Substituted cyclic amino acids as pharmaceutical agents |
| HU218681B (hu) | 1997-07-25 | 2000-10-30 | Sanofi-Synthelabo | Eljárás 1,3-diaza-spiro(4,4)non-1-én-4-on-származékok előállitására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek |
| US6162922A (en) * | 1998-01-30 | 2000-12-19 | Bristol-Myers Squibb Co. | Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst |
| EP1066262A4 (en) * | 1998-03-25 | 2004-09-01 | Bristol Myers Squibb Co | IMIDAZOLONE ANOREXIGENAL AGENTS: ACYCLIC DERIVATIVES I |
| KR19990081093A (ko) * | 1998-04-25 | 1999-11-15 | 조생현 | 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법 |
| DE19820064A1 (de) * | 1998-05-06 | 1999-11-11 | Hoechst Marion Roussel De Gmbh | Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| FR2780403B3 (fr) | 1998-06-24 | 2000-07-21 | Sanofi Sa | Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant |
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| AU750129C (en) * | 1998-07-29 | 2003-02-20 | Ihara Chemical Industry Co. Ltd. | Di- or tri-fluoromethanesulfonyl anilide derivatives, process for the preparation of them and herbicides containing them as the active ingredient |
| BR9916576A (pt) | 1998-12-23 | 2001-10-02 | Novartis Ag | Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 |
| US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| AR033390A1 (es) | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| RU2263675C2 (ru) * | 2001-09-21 | 2005-11-10 | Бориюнг Фармасьютикал Ко., Лтд. | Способ получения пиримидинонового соединения и его фармацевтически приемлемых солей |
| FR2831446B1 (fr) * | 2001-10-26 | 2004-03-05 | Sanofi Synthelabo | Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| GB0316546D0 (en) | 2003-07-15 | 2003-08-20 | Novartis Ag | Process for the manufacture of organic compounds |
| RU2422450C2 (ru) | 2003-11-19 | 2011-06-27 | Метабазис Терапеутикс, Инк. | Новые фосфорсодержащие тиромиметики |
| GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
| NZ549535A (en) | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| AU2005249794A1 (en) | 2004-06-04 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical composition containing irbesartan |
| WO2005122699A2 (en) * | 2004-06-16 | 2005-12-29 | Matrix Laboratories Ltd | An improved process for the preparation of n-substituted hetero cyclic derivatives |
| SI21849A (sl) | 2004-07-29 | 2006-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Priprava hidrokloridnih soli tetrazolskega derivata |
| TWI346108B (en) | 2004-08-23 | 2011-08-01 | Bristol Myers Squibb Co | A method for preparing irbesartan and intermediates thereof |
| CN101102755B (zh) | 2004-10-08 | 2013-01-02 | 诺瓦提斯公司 | 肾素抑制剂在制备预防或治疗舒张功能障碍或舒张性心力衰竭的药物中的用途 |
| GB2419592A (en) | 2004-10-26 | 2006-05-03 | Cipla Ltd | Process for the preparation of irbesartan hydrochloride |
| EP1806332A4 (en) | 2004-10-27 | 2010-03-31 | Daiichi Sankyo Co Ltd | BENZOL CONNECTION WITH TWO OR MORE SUBSIDIARIES |
| FR2886642B1 (fr) * | 2005-06-06 | 2008-05-30 | Sanofi Aventis Sa | Sels alcalino-terreux d'irbesartan et leur preparation |
| EP1749828A1 (en) | 2005-08-04 | 2007-02-07 | Farmaprojects S.L. | Process for preparing an angiotensin II receptor antagonist |
| EP1948641A1 (en) | 2005-10-28 | 2008-07-30 | Alembic Limited | An improved process for preparation of irbesartan |
| ES2340701T3 (es) | 2006-01-09 | 2010-06-08 | Krka, D.D., Novo Mesto | Composicion farmaceutica solida que comprende irbesartan. |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| EP1918288A1 (en) | 2006-11-02 | 2008-05-07 | Cadila Pharmaceuticals Limited | A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension |
| KR20090115951A (ko) | 2007-03-01 | 2009-11-10 | 프로비오드룩 아게 | 글루타미닐 사이클라제 저해제의 신규 용도 |
| ES2533484T3 (es) | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Derivados de tiourea como inhibidores de la glutaminil ciclasa |
| CN103601792B (zh) | 2007-06-04 | 2016-06-29 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| PE20090818A1 (es) | 2007-10-16 | 2009-07-24 | Novartis Ag | Compuestos heterociclicos como moduladores de los receptores de npy y2 |
| PT2065035E (pt) | 2007-11-28 | 2010-10-04 | Lesvi Laboratorios Sl | Formulações farmacêuticas contendo irbesartan |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2009149734A1 (en) * | 2008-06-13 | 2009-12-17 | Ratiopharm Gmbh | Process for the preparation of irbesartan and intermediate products |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2194050A1 (en) | 2008-12-08 | 2010-06-09 | KRKA, tovarna zdravil, d.d., Novo mesto | A new process for the preparation of irbesartan |
| WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
| KR101755737B1 (ko) | 2009-09-11 | 2017-07-07 | 프로비오드룩 아게 | 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체 |
| HUP0900788A2 (en) | 2009-12-16 | 2011-11-28 | Sanofi Aventis | Process for producing 4-bromomethyl-biphenyl derivatives |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| CA2789440C (en) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| BR112014014527A2 (pt) | 2011-12-15 | 2017-06-13 | Takeda Pharmaceuticals Usa Inc | combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros |
| PL223830B1 (pl) | 2012-04-03 | 2016-11-30 | Univ Jagiellonski | Pochodne aromatycznych imidazolidynonów i ich zastosowanie |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| WO2015012205A1 (ja) | 2013-07-23 | 2015-01-29 | 第一三共株式会社 | 高血圧症の予防又は治療のための医薬 |
| WO2017164208A1 (ja) | 2016-03-24 | 2017-09-28 | 第一三共株式会社 | 腎疾患の治療のための医薬 |
| FI3648761T3 (fi) | 2017-07-07 | 2024-05-21 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartaani kissan hypertension ehkäisemiseksi tai hoitamiseksi |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| WO2024240633A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan |
| WO2025125409A1 (en) | 2023-12-15 | 2025-06-19 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3340595A1 (de) * | 1983-11-10 | 1985-05-23 | Hoechst Ag, 6230 Frankfurt | Imidazolinone, verfahren zu ihrer herstellung und ihre verwendung im pflanzenschutz |
| DE3545597A1 (de) * | 1985-12-21 | 1987-07-02 | Celamerck Gmbh & Co Kg | Neue herbizid wirksame imidazolinone |
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US4820843A (en) * | 1987-05-22 | 1989-04-11 | E. I. Du Pont De Nemours And Company | Tetrazole intermediates to antihypertensive compounds |
| EP0303863A3 (en) * | 1987-08-17 | 1991-10-23 | American Cyanamid Company | Benzenesulfonyl carboxamide compounds, intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents |
| US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| EP0407342A3 (en) * | 1989-07-06 | 1991-07-10 | Ciba-Geigy Ag | Pyrimidine derivatives |
| EP0412594B1 (en) * | 1989-07-28 | 1996-01-03 | Merck & Co. Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
| EP0411507B1 (en) * | 1989-08-02 | 1994-10-26 | Takeda Chemical Industries, Ltd. | Pyrazole derivatives, their production and use |
| US5100897A (en) * | 1989-08-28 | 1992-03-31 | Merck & Co., Inc. | Substituted pyrimidinones as angiotensin ii antagonists |
| IL99372A0 (en) * | 1990-09-10 | 1992-08-18 | Ciba Geigy Ag | Azacyclic compounds |
-
1991
- 1991-03-19 TW TW080102155A patent/TW201738B/zh not_active IP Right Cessation
- 1991-03-19 PT PT97078A patent/PT97078B/pt not_active IP Right Cessation
- 1991-03-19 IE IE091391A patent/IE910913A1/en not_active IP Right Cessation
- 1991-03-19 NZ NZ237476A patent/NZ237476A/en unknown
- 1991-03-20 PL PL91304152A patent/PL166581B1/pl unknown
- 1991-03-20 EP EP91400745A patent/EP0454511B1/fr not_active Expired - Lifetime
- 1991-03-20 DK DK91400745T patent/DK0454511T3/da active
- 1991-03-20 HU HU9302497A patent/HUT67648A/hu active IP Right Revival
- 1991-03-20 IL IL11082091A patent/IL110820A/en not_active IP Right Cessation
- 1991-03-20 PL PL91293015A patent/PL165945B1/pl unknown
- 1991-03-20 SK SK1256-98A patent/SK283197B6/sk not_active IP Right Cessation
- 1991-03-20 ES ES91400745T patent/ES2119764T3/es not_active Expired - Lifetime
- 1991-03-20 IL IL9761291A patent/IL97612A/en active Protection Beyond IP Right Term
- 1991-03-20 PL PL91304153A patent/PL166403B1/pl unknown
- 1991-03-20 DE DE69129606T patent/DE69129606T2/de not_active Expired - Lifetime
- 1991-03-20 KR KR1019910701647A patent/KR0175310B1/ko not_active Expired - Lifetime
- 1991-03-20 UA UA5010343A patent/UA42669A/uk unknown
- 1991-03-20 SG SG1996005558A patent/SG49053A1/en unknown
- 1991-03-20 RU SU5010343/04A patent/RU2099331C1/ru active
- 1991-03-20 AT AT91400745T patent/ATE167475T1/de active
- 1991-03-20 HU HU603/91A patent/HU221188B1/hu unknown
- 1991-03-20 HU HU9302497A patent/HU223141B1/hu active IP Right Grant
- 1991-03-20 CA CA002057913A patent/CA2057913C/en not_active Expired - Lifetime
- 1991-03-20 DE DE1999175029 patent/DE19975029I2/de active Active
- 1991-03-20 WO PCT/FR1991/000224 patent/WO1991014679A1/fr active IP Right Grant
- 1991-03-20 AU AU75610/91A patent/AU641005B2/en not_active Expired
- 1991-03-20 JP JP3506471A patent/JP2868313B2/ja not_active Expired - Lifetime
- 1991-03-20 SK SK745-91A patent/SK280096B6/sk not_active IP Right Cessation
- 1991-03-20 CZ CS1991745A patent/CZ287064B6/cs not_active IP Right Cessation
- 1991-03-20 MY MYPI91000464A patent/MY115638A/en unknown
- 1991-11-19 FI FI915458A patent/FI103407B/fi active Protection Beyond IP Right Term
- 1991-11-19 NO NO914528A patent/NO301977B1/no not_active IP Right Cessation
-
1992
- 1992-06-26 MX MX9203586A patent/MX9203586A/es active IP Right Grant
-
1993
- 1993-02-25 LV LVP-93-147A patent/LV10439B/en unknown
-
1994
- 1994-08-30 IL IL11082094A patent/IL110820A0/xx unknown
-
1996
- 1996-01-15 CZ CZ1996120A patent/CZ287225B6/cs not_active IP Right Cessation
-
1997
- 1997-12-10 JP JP9339895A patent/JPH10279566A/ja active Pending
-
1998
- 1998-08-21 LU LU90279C patent/LU90279I2/fr unknown
- 1998-09-16 NO NO1998021C patent/NO1998021I1/no unknown
- 1998-12-02 NL NL980039C patent/NL980039I2/nl unknown
-
1999
- 1999-03-05 NL NL990006C patent/NL990006I2/nl unknown
- 1999-03-12 LU LU90371C patent/LU90371I2/xx unknown
- 1999-12-09 NO NO1999025C patent/NO1999025I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA42669A (uk) | Антагоністи ангіотензину ii, спосіб їх отримання (варіанти), проміжна сполука (варіанти), спосіб їх отримання та фармацевтична композиція | |
| BR9611618A (pt) | Composto processo para sua preparação composição farmacêutica e utilização de um compostos | |
| ES2117795T3 (es) | Derivados de acetamida y su uso como modificadores del comportamiento de toma alimentaria. | |
| PT1140916E (pt) | Acetais heteroarilo ciclicos | |
| KR900701780A (ko) | 5'-인돌리닐-5β-아미도메틸옥사졸리딘-2-온, 3-(융합-고리치환된)페닐-5β-아미도메틸옥사졸리딘-2-온 및 3-(질소 치환된)페닐-5β-아미도메틸옥사졸리딘-2-온 | |
| ES2061663T3 (es) | Derivados de carbamoilpirrolidina, su uso y preparacion. | |
| WO1998009953A3 (de) | Azinyloxy- und phenoxy-diaryl-carbonsäure derivate, deren herstellung und deren verwendung als gemischte eta/etb endothelin-rezeptorantagonist | |
| EE9700282A (et) | Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine | |
| EP0829474A4 (en) | INDAZOLE DERIVATIVES WITH A CYCLIC AMINO GROUP | |
| DK0527494T3 (da) | Præparat indeholdende rhodacyanin-farvestoffer til behandling af cancer | |
| ATE72431T1 (de) | 5-gliedrige heterocyclische angiotensinumwandlungsenzym-inhibitoren. | |
| ATE173730T1 (de) | N-(piperidinyl-1-alkyl)-substituierte cyclohexancarbonsäureamide als 5ht1a rezeptor antagonisten | |
| DE69101141D1 (de) | Neue Guanidinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen. | |
| MY131762A (en) | Pharmaceutical compounds | |
| ES8702381A1 (es) | Procedimiento para la obtencion de oxazolidinonas trisusti- tuidas | |
| DK0508955T3 (da) | Anvendelse af 2-iminothiazolidin-4-onderivater som nye lægemidler | |
| DK0782574T3 (da) | Bicycliske carboxiamider som 5-HT1A-receptorligander | |
| KR940014386A (ko) | 3-(6-퀴놀릴메틸)-4h-이미다졸-4-온 유도체, 이것의 제법 및 치료에의 이용 | |
| ES463570A1 (es) | Un procedimiento para la preparacion de nuevos compuestos triciclicos biologicamente activos | |
| GB1437799A (en) | Benzimidazolinone compounds | |
| DK0882138T3 (da) | Stereoselektiv fremstilling af 2-substituerede ravsyrederivater | |
| DE3862426D1 (de) | 2-selenomethyl-1,4-dihydropyridine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| DE69102309D1 (de) | N-cycloalkyl-Alkylamine, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und Zwischenprodukte zu ihrer Synthese. | |
| GB1414155A (en) | Triazole derivatives | |
| DE69116680D1 (de) | Imidazol-2-yl-derivate von bicyclischen verbindungen und verfahren zu deren herstellung |